Hemab Therapeutics Hldgs Financials - Benzinga

Hemab Therapeutics Holdings Inc

COAGNASDAQ

Trade with Public

Trade with Public

$44.84

-4.65-9.4%

가까이에: Aug 28, 5:00 PM EST

$44.84

N/A

시간외: Aug 28, 4:00 PM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 주식 보고서

Hemab Therapeutics Hldgs Financials

Hemab Therapeutics Hldgs (COAG) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Hemab Therapeutics Hldgs Q2 EPS $(0.80) Misses $(0.52) Estimate

Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.52) by 53.85 percent. This is a 93.8 percent increase over losses of $(12.91) per

Benzinga Newsdesk

Earnings Scheduled For May 21, 2026

Benzinga Insights

PRO
Hemab Therapeutics Hldgs Q1 EPS $(23.98) Down From $(16.18) YoY

Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(23.98) per share. This is a 48.21 percent decrease over losses of $(16.18) per share from the same period last year.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved